166 related articles for article (PubMed ID: 17596581)
1. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Clavarezza M; Del Mastro L; Pronzato P; Bruzzi P; Venturini M
J Natl Cancer Inst; 2007 Jul; 99(13):1050-1; author reply 1051-2. PubMed ID: 17596581
[No Abstract] [Full Text] [Related]
2. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Warren JL; Brown ML
J Natl Cancer Inst; 2007 Jul; 99(13):1050; author reply 1051-2. PubMed ID: 17596580
[No Abstract] [Full Text] [Related]
3. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy?
Touw IP; Bontenbal M
J Natl Cancer Inst; 2007 Feb; 99(3):183-6. PubMed ID: 17284707
[No Abstract] [Full Text] [Related]
6. Acute myeloid leukaemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Ferretti G; Papaldo P
Breast Cancer Res Treat; 2008 May; 109(1):187-8. PubMed ID: 17616805
[No Abstract] [Full Text] [Related]
7. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
J Clin Oncol; 2005 Jun; 23(18):4179-91. PubMed ID: 15961765
[TBL] [Abstract][Full Text] [Related]
8. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family members.
Padmanabhan A; Baker JA; Zirpoli G; Sait SN; Ford LA; Moysich KB; Baer MR
Leuk Res; 2008 Dec; 32(12):1820-3. PubMed ID: 18468682
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte colony-stimulating factors and risk of acute myeloid leukemia and myelodysplastic syndrome.
Lyman GH; Kuderer NM
Cancer Treat Res; 2011; 157():167-78. PubMed ID: 21052956
[No Abstract] [Full Text] [Related]
11. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
Calip GS; Malmgren JA; Lee WJ; Schwartz SM; Kaplan HG
Breast Cancer Res Treat; 2015 Nov; 154(1):133-43. PubMed ID: 26450505
[TBL] [Abstract][Full Text] [Related]
12. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.
Morton LM; Dores GM; Schonfeld SJ; Linet MS; Sigel BS; Lam CJK; Tucker MA; Curtis RE
JAMA Oncol; 2019 Mar; 5(3):318-325. PubMed ID: 30570657
[TBL] [Abstract][Full Text] [Related]
13. [Acute myelogenous leukemia and myelodysplastic syndrome after treatment with cytostatic agents].
Abrahamsen AF
Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2542-5. PubMed ID: 11070993
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Muss HB; Berry DA; Cirrincione C; Budman DR; Henderson IC; Citron ML; Norton L; Winer EP; Hudis CA;
J Clin Oncol; 2007 Aug; 25(24):3699-704. PubMed ID: 17704418
[TBL] [Abstract][Full Text] [Related]
15. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience.
Smith RE
Clin Breast Cancer; 2003 Oct; 4(4):273-9. PubMed ID: 14651772
[TBL] [Abstract][Full Text] [Related]
16. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
[TBL] [Abstract][Full Text] [Related]
17. Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer.
Du XL; Zhang Y; Hardy D
Cancer Causes Control; 2016 May; 27(5):695-707. PubMed ID: 27059219
[TBL] [Abstract][Full Text] [Related]
18. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence.
Lipshultz SE; Lipsitz SR; Orav EJ
J Clin Oncol; 2007 Jul; 25(21):3179; author reply 3180. PubMed ID: 17634500
[No Abstract] [Full Text] [Related]
19. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
Arana-Yi C; Block AW; Sait SN; Ford LA; Barcos M; Baer MR
Leuk Res; 2008 Jul; 32(7):1043-8. PubMed ID: 18093651
[TBL] [Abstract][Full Text] [Related]
20. Myelodysplastic syndrome/acute myelogenous leukaemia after adjuvant chemotherapy with pyrimidine anti-metabolites in three patients.
Pitini V; Arrigo C; Aloi G; Righi M; Falduto M; Teti D
Haematologica; 2001 Oct; 86(10):E30. PubMed ID: 11602437
[No Abstract] [Full Text] [Related]
[Next] [New Search]
